{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:21:22Z","timestamp":1794835282805,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fondazione Greta ETS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1245\/s10434-026-20465-y","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:44:52Z","timestamp":1788803092000},"page":"10930-10941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Breast-Conserving Surgery Versus Mastectomy After Neoadjuvant Therapy: A Survival Analysis"],"prefix":"10.1245","volume":"33","author":[{"given":"Giuseppe","family":"Catanuto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Martorana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Montagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio B.","family":"Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Parrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Cinquini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"5","key":"20465_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/bjs.10807","volume":"105","author":"A Karakatsanis","year":"2018","unstructured":"Karakatsanis A, Tasoulis MK, W\u00e4rnberg F, Nilsson G, MacNeill F. Meta-analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer. Br J Surg. 2018;105(5):469\u201381. https:\/\/doi.org\/10.1002\/bjs.10807.","journal-title":"Br J Surg."},{"issue":"6","key":"20465_CR2","doi-asserted-by":"publisher","first-page":"109643","DOI":"10.1016\/j.ejso.2025.109643","volume":"51","author":"G Catanuto","year":"2025","unstructured":"Catanuto G, Gentile D, Martorana F, et al. Clinico-pathological features predicting indication to mastectomy in breast cancer patients achieving complete response after neoadjuvant therapy: a retrospective analysis of the EUSOMA database. Eur J Surg Oncol. 2025;51(6):109643. https:\/\/doi.org\/10.1016\/j.ejso.2025.109643.","journal-title":"Eur J Surg Oncol."},{"issue":"12","key":"20465_CR3","doi-asserted-by":"publisher","first-page":"108732","DOI":"10.1016\/j.ejso.2024.108732","volume":"50","author":"D Gentile","year":"2024","unstructured":"Gentile D, Martorana F, Karakatsanis A, et al. Predictors of mastectomy in breast cancer patients with complete remission of primary tumor after neoadjuvant therapy: a retrospective study. Eur J Surg Oncol. 2024;50(12):108732. https:\/\/doi.org\/10.1016\/j.ejso.2024.108732.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"20465_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"B Asselain","year":"2018","unstructured":"Asselain B, Barlow W, Bartlett J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(17)30777-5.","journal-title":"Lancet Oncol."},{"issue":"14","key":"20465_CR5","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1002\/cncr.31518","volume":"124","author":"A Valachis","year":"2018","unstructured":"Valachis A, Mamounas EP, Mittendorf EA, et al. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: an international collaboration and individual patient meta-analysis. Cancer. 2018;124(14):2923\u201330. https:\/\/doi.org\/10.1002\/cncr.31518.","journal-title":"Cancer."},{"issue":"5","key":"20465_CR6","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1245\/s10434-015-4404-8","volume":"22","author":"P Cortazar","year":"2015","unstructured":"Cortazar P, Geyer CE. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015;22(5):1441\u20136. https:\/\/doi.org\/10.1245\/s10434-015-4404-8.","journal-title":"Ann Surg Oncol."},{"issue":"21","key":"20465_CR7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391(21):1981\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2409932.","journal-title":"N Engl J Med."},{"key":"20465_CR8","doi-asserted-by":"publisher","first-page":"100712","DOI":"10.1016\/j.lana.2024.100712","volume":"32","author":"X He","year":"2024","unstructured":"He X, Ji J, Qdaisat A, Esteva FJ, Yeung SCJ. Long-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-positive breast cancer after preoperative systemic therapy: an observational cohort study. Lancet Reg Heal Am. 2024;32:100712. https:\/\/doi.org\/10.1016\/j.lana.2024.100712.","journal-title":"Lancet Reg Heal Am."},{"issue":"11","key":"20465_CR9","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1001\/jamaoncol.2021.3690","volume":"7","author":"WF Symmans","year":"2021","unstructured":"Symmans WF, Yau C, Chen YY, et al. Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial. JAMA Oncol. 2021;7(11):1654\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3690.","journal-title":"JAMA Oncol."},{"issue":"9","key":"20465_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med."},{"issue":"5","key":"20465_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14737140.2024.2341729","volume":"24","author":"H O\u2019Rourke","year":"2024","unstructured":"O\u2019Rourke H, Hart C, De Boer RH. Current usage of pembrolizumab in triple negative breast cancer (TNBC). Expert Rev Anticancer Ther. 2024;24(5):253\u201361. https:\/\/doi.org\/10.1080\/14737140.2024.2341729.","journal-title":"Expert Rev Anticancer Ther."},{"issue":"3","key":"20465_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/cco-20-123","volume":"9","author":"M Takada","year":"2020","unstructured":"Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chinese Clin Oncol. 2020;9(3):32\u201332. https:\/\/doi.org\/10.21037\/cco-20-123.","journal-title":"Chinese Clin Oncol."},{"key":"20465_CR13","doi-asserted-by":"publisher","first-page":"112885","DOI":"10.1016\/j.ejca.2023.03.042","volume":"190","author":"G Villacampa","year":"2023","unstructured":"Villacampa G, Matikas A, Oliveira M, Prat A, Pascual T, Papakonstantinou A. Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. Eur J Cancer. 2023;190:112885. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.042.","journal-title":"Eur J Cancer."},{"issue":"5","key":"20465_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6650.","journal-title":"JAMA Oncol."},{"issue":"11","key":"20465_CR15","doi-asserted-by":"publisher","first-page":"e2342107","DOI":"10.1001\/jamanetworkopen.2023.42107","volume":"6","author":"M Takahashi","year":"2023","unstructured":"Takahashi M, Cort\u00e9s J, Dent R, et al. Pembrolizumab plus chemotherapy followed by pembrolizumab in patients with early triple-negative breast cancer: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023;6(11):e2342107. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.42107.","journal-title":"JAMA Netw Open."},{"issue":"9938","key":"20465_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (London, England). 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet (London, England)."},{"issue":"12","key":"20465_CR17","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.ejso.2016.10.011","volume":"42","author":"C Criscitiello","year":"2016","unstructured":"Criscitiello C, Curigliano G, Burstein HJ, et al. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: are we losing the opportunity? Eur J Surg Oncol. 2016;42(12):1780\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2016.10.011.","journal-title":"Eur J Surg Oncol."},{"key":"20465_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.03.023","volume":"97","author":"C Criscitiello","year":"2018","unstructured":"Criscitiello C, Golshan M, Barry WT, et al. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: a meta-analysis. Eur J Cancer. 2018;97:1\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2018.03.023.","journal-title":"Eur J Cancer."},{"issue":"2","key":"20465_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/cancers16020376","volume":"16","author":"C Tinterri","year":"2024","unstructured":"Tinterri C, Fernandes B, Zambelli A, et al. The impact of different patterns of residual disease on long-term oncological outcomes in breast cancer patients treated with neo-adjuvant chemotherapy. Cancers. 2024;16(2):376. https:\/\/doi.org\/10.3390\/cancers16020376.","journal-title":"Cancers"},{"issue":"10","key":"20465_CR20","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/jjco\/hyab117","volume":"51","author":"J Fei","year":"2021","unstructured":"Fei J, Wang GQ, Meng YY, et al. Breast cancer subtypes affect the ultrasound performance for axillary lymph node status evaluation after neoadjuvant chemotherapy: a retrospective analysis. Jpn J Clin Oncol. 2021;51(10):1509\u201314. https:\/\/doi.org\/10.1093\/jjco\/hyab117.","journal-title":"Jpn J Clin Oncol."},{"key":"20465_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.breast.2018.02.028","volume":"39","author":"A Baumgartner","year":"2018","unstructured":"Baumgartner A, Tausch C, Hosch S, et al. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. The Breast. 2018;39:19\u201323. https:\/\/doi.org\/10.1016\/j.breast.2018.02.028.","journal-title":"The Breast."},{"issue":"11","key":"20465_CR22","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.crad.2006.07.004","volume":"61","author":"P Belli","year":"2006","unstructured":"Belli P, Costantini M, Malaspina C, Magistrelli A, LaTorre G, Bonomo L. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol. 2006;61(11):946\u201353. https:\/\/doi.org\/10.1016\/j.crad.2006.07.004.","journal-title":"Clin Radiol."},{"issue":"6","key":"20465_CR23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/jso.25663","volume":"120","author":"SF Sener","year":"2019","unstructured":"Sener SF, Sargent RE, Lee C, et al. MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer. J Surg Oncol. 2019;120(6):903\u201310. https:\/\/doi.org\/10.1002\/jso.25663.","journal-title":"J Surg Oncol."},{"issue":"1","key":"20465_CR24","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1186\/s12885-015-1664-4","volume":"15","author":"ML Marinovich","year":"2015","unstructured":"Marinovich ML, Macaskill P, Irwig L, et al. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer. 2015;15(1):662. https:\/\/doi.org\/10.1186\/s12885-015-1664-4.","journal-title":"BMC Cancer."},{"issue":"6","key":"20465_CR25","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/bjc.2013.473","volume":"109","author":"ML Marinovich","year":"2013","unstructured":"Marinovich ML, Macaskill P, Irwig L, et al. Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. Br J Cancer. 2013;109(6):1528\u201336. https:\/\/doi.org\/10.1038\/bjc.2013.473.","journal-title":"Br J Cancer."},{"key":"20465_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.clinimag.2023.06.007","volume":"101","author":"L Kwak","year":"2023","unstructured":"Kwak L, Santa-Maria C, Di Carlo P, et al. Can breast MRI predict pathologic response following neoadjuvant chemotherapy for breast cancer? A retrospective cohort study. Clin Imaging. 2023;101:105\u201312. https:\/\/doi.org\/10.1016\/j.clinimag.2023.06.007.","journal-title":"Clin Imaging."},{"issue":"3","key":"20465_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/cncr.33929","volume":"128","author":"A Mamtani","year":"2022","unstructured":"Mamtani A, Sevilimedu V, Le T, Morrow M, Barrio AV. Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy? Cancer. 2022;128(3):471\u20138. https:\/\/doi.org\/10.1002\/cncr.33929.","journal-title":"Cancer."},{"issue":"5","key":"20465_CR28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3390\/cancers17050766","volume":"17","author":"D Gentile","year":"2025","unstructured":"Gentile D, Canzian J, Barbieri E, Di Maria Grimaldi S, De Sanctis R, Tinterri C. Superior survival and lower recurrence outcomes with breast-conserving surgery compared to mastectomy following neoadjuvant therapy in 607 breast cancer patients. Cancers. 2025;17(5):766. https:\/\/doi.org\/10.3390\/cancers17050766.","journal-title":"Cancers."},{"issue":"43","key":"20465_CR29","doi-asserted-by":"publisher","first-page":"e8367","DOI":"10.1097\/MD.0000000000008367","volume":"96","author":"Y Sun","year":"2017","unstructured":"Sun Y, Liao M, He L, Zhu C. Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy. Medicine (Baltimore). 2017;96(43):e8367. https:\/\/doi.org\/10.1097\/MD.0000000000008367.","journal-title":"Medicine (Baltimore)."},{"issue":"12","key":"20465_CR30","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1097\/COC.0000000000000456","volume":"41","author":"RL Arlow","year":"2018","unstructured":"Arlow RL, Paddock LE, Niu X, et al. Breast-conservation therapy after neoadjuvant chemotherapy does not compromise 10-year breast cancer-specific mortality. Am J Clin Oncol. 2018;41(12):1246\u201351. https:\/\/doi.org\/10.1097\/COC.0000000000000456.","journal-title":"Am J Clin Oncol."},{"key":"20465_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1293288","author":"GB Nobrega","year":"2023","unstructured":"Nobrega GB, Mota BS, de Freitas GB, et al. Locally advanced breast cancer: breast-conserving surgery and other factors linked to overall survival after neoadjuvant treatment. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1293288.","journal-title":"Front Oncol."},{"issue":"5","key":"20465_CR32","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1245\/s10434-022-12993-0","volume":"30","author":"S Gwark","year":"2023","unstructured":"Gwark S, Kim HJ, Kim J, et al. Survival after breast-conserving surgery compared with that after mastectomy in breast cancer patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2023;30(5):2845\u201353. https:\/\/doi.org\/10.1245\/s10434-022-12993-0.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20465-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:34:25Z","timestamp":1794832465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20465-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":32,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["20465"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20465-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was based on publicly available, deidentified data from the Surveillance, Epidemiology, and End Results (SEER) database. According to institutional and national guidelines, ethical approval and informed consent were not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}